Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELONSEN: Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis
NCT06730061Phase 3Active, not recruiting
- Sponsor
- Ipsen
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elafibranor in primary biliary cholangitis (PBC), sponsored by Ipsen. Primary endpoint: Composite Biochemical Response (ALP and TB) at 52 weeks. Started Jan 2025; status: active, not recruiting.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06730061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730061.